Does the timing of acute rejection matter with the graft outcome in kidney transplantation?  by Kim, Myung-Gyu
Kidney Res Clin Pract 34 (2015) 123–124journal homepage: http://www.krcp-ksn.com
Kidney Research and Clinical Practice2211-9
CC BY-
http://Contents lists available at ScienceDirectEditorialDoes the timing of acute rejection matter with the graft outcome
in kidney transplantation?Acute rejection (AR) is a major complication of kidney
transplantation (KT). Although advances in immunosuppres-
sive therapy have reduced the incidence of AR, the effect of AR
on allograft dysfunction remains an important issue. The
number of AR episodes, their severity and type, patient
responses to the treatment, and the timing of AR are all
potential determinants of graft outcomes [1,2]. Of special
interest to many researchers is the role of timing of AR
episodes, and what effects timing has on graft outcomes. The
primary reason for this interest is that the physiological
environment of the allograft changes gradually with time.
After KT, dosing of immunosuppressive therapy decreases over
time, and graft function gradually declines because of immu-
nologic damage, infection, aging, and chronic exposure to
calcineurin inhibitors. Additionally, immune responses to the
allograft might be mediated by different mechanisms related
to how much time has passed after transplantation [3,4].
In this issue of Kidney Research and Clinical Practice, Koo
et al [5] investigated the impact of time of AR on long-term
graft survival in a single-center cohort. They enrolled 709
patients who had undergone KT between 2000 and 2009 and
found that both early- and late-onset AR signiﬁcantly inﬂu-
ences graft outcomes.
Previously, several studies examined the inﬂuence of timing
of AR on graft outcomes. In 2003, Sijpkens et al [4] found that
AR occurring more than 3 months after KT was associated with
poorer graft outcomes than AR that occurred during the ﬁrst 3
months. Interestingly, they also found that human leukocyte
antigen (HLA) Class I mismatches predicted late AR, whereas
HLA Class II mismatches were associated with early AR. This
suggests that direct and indirect pathways of allorecognition
may play a role in the pathophysiology of early and late AR,
respectively. In 2008, Opelz and Dohler [6] found that late AR
is more severe than early AR, as reﬂected by incomplete
functional recovery. Late AR was more difﬁcult to reverse by
rejection treatment than early AR and therefore led to poorer
long-term outcomes. Most recently, Krisl et al [7] examined
how the type of AR, in addition to timing, affects graft
outcomes. The authors found that late-onset antibody-
mediated rejection was associated with signiﬁcantly worse
graft survival compared with other types and timing of AR,132/$ - see front matter Copyright & 2015. The Korean Society of Nep
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dx.doi.org/10.1016/j.krcp.2015.07.004suggesting an important role of humoral immunity in graft
outcomes.
Despite these results, it is difﬁcult to conclude that the
timing of AR is a critical factor determining graft outcomes.
Recent immunosuppressive strategies using tacrolimus and
mycophenolate mofetil have contributed to improvement of
graft outcomes [8,9]; earlier studies, however, included many
patients taking cyclosporine with azathioprine. Therefore, the
results are not sufﬁciently informative about the effects of AR
in the current era of immunosuppression. Additionally,
70–100% of donors in previous studies were deceased donors.
However, living donors account for a large proportion of the
donor population in Asian countries. In Korea, more than 50%
of KTs use kidneys from living donors [10]. Different donor
characteristics can lead to varied immunologic environments
and thus inﬂuence the effect of AR on graft outcomes. In
addition, we should consider the role of relatively short cold
ischemic times in Korea because cold ischemia enhances the
immune response to an allograft and affects clinical features of
AR. Consequently, the impact of early and late AR on graft
survival in Korea needs to be investigated using regional data.
In the present study, Koo et al [5] examined these issues
with a cohort of recent KT patients in a single center. They
found that there were no signiﬁcant differences in graft
survival according to the timing of AR, although both early
and late AR had negative effects on outcomes compared with
no AR. As a result, they conclude that both early and late AR
present major barriers to improving long-term graft survival.
Additionally, male sex and HLA mismatch were risk factors for
early AR, whereas younger age of recipient and high panel-
reactive antibody levels predicted late AR. However, this study
has limitations in the analysis of the factors that may have
affected the results, such as baseline renal function at rejec-
tion, AR severity, AR consequences, viral infections, de novo
renal disease, and histological ﬁndings of microcirculatory
inﬂammation and chronic changes.
The major conclusion of this study is that compared with
nonimmunologic factors, AR was the most signiﬁcant risk
factor associated with poor graft survival. To improve graft
survival, we should aim to reduce the number of AR episodes
and their severity and enhance responses to treatmenthrology. Published by Elsevier. This is an open access article under the
Editorial / Kidney Res Clin Pract 34 (2015) 123–124124regardless of the timing of AR onset. In particular, an important
issue raised by this study was whether early AR is a signiﬁcant
risk factor for graft failure, and the authors showed the
importance of early AR in graft survival. Besides, antibody-
associated graft injury needs to be considered a major risk
factor of late-onset AR because high panel-reactive antibody
was associated with late AR. Although there is a lack of precise
data about the type of AR, implementing steps such as
immunologic monitoring, early detection, and treatment of
humoral immune response should be critical for improving
prognosis. Finally, this study is valuable because the authors
examined the inﬂuence of AR timing on graft survival in
patients receiving the current standards of immunosuppres-
sive therapy. We are encouraged by the recent establishment
of the national database, Korean Organ Transplant Registry
[10]. Comparable with the Scientiﬁc Registry of Transplant
Recipient, the Collaborative Transplant Study, and the Australia
and New Zealand Dialysis and Transplant Registry in other
countries, we have our own transplantation database system
that will be used for large-scale researches. The Korean Organ
Transplant Registry data will be of help to more clearly deﬁne
the impact of AR and related clinical features on patient
outcomes.Conﬂicts of interest
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